Affinity DataKi: 3.80E+3nMAssay Description:Inhibition constant against alpha-chymotrypsinMore data for this Ligand-Target Pair
Affinity DataKi: >2.00E+6nMAssay Description:Inhibition constant of the compound against Alpha-chymotrypsin inhibitor was determinedMore data for this Ligand-Target Pair
TargetCorticotropin-releasing factor receptor 1(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataIC50: 6.10nMAssay Description:Antagonist activity at human CRF1 receptorMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of recombinant VEGFR-2 (unknown origin)More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataIC50: 22nMAssay Description:Inhibition of recombinant FGFR-1 (unknown origin)More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataIC50: 26nMAssay Description:Inhibition of human recombinant FGFR-1More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataIC50: 26nMAssay Description:Inhibition of human recombinant VEGFR-2More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataIC50: 26nMAssay Description:Inhibition of recombinant VEGFR-2 (unknown origin)More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataIC50: 28nMAssay Description:Inhibition of recombinant FGFR-1 (unknown origin)More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataIC50: 28nMAssay Description:Inhibition of human recombinant FGFR-1More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataIC50: 28nMAssay Description:Inhibition of human recombinant VEGFR-2More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataIC50: 78nMAssay Description:Inhibition of human recombinant VEGFR-2More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataIC50: 760nMAssay Description:Inhibition of human recombinant FGFR-1More data for this Ligand-Target Pair
TargetCorticotropin-releasing factor-binding protein(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:Binding affinity to CRF-binding protein (unknown origin)More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of human recombinant VEGFR-2More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of human recombinant FGFR-1More data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2C8 in human liver microsomes assessed as paclitaxel 6alpha-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence ...More data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2C8 in human liver microsomes assessed as paclitaxel 6alpha-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPHMore data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2C9 in human liver microsomes assessed as paclitaxel 6alpha-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence ...More data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2B6 in human liver microsomes assessed as bupropion hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPHMore data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2A6 in human liver microsomes assessed as coumarin 7-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADP...More data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2B6 in human liver microsomes assessed as bupropion hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPHMore data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP1A2 in human liver microsomes assessed as phenacetin O-deethylation preincubated for 15 mins by LC-MS/MS analysis in presence of NAD...More data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPHMore data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2A6 in human liver microsomes assessed as coumarin 7-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPHMore data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 3 mins by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2E1 in human liver microsomes assessed as chlorzoxazone 6-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPHMore data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP1A2 in human liver microsomes assessed as phenacetin O-deethylation after 3 mins by LC-MS/MS analysis in presence of NADPHMore data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2C19 in human liver microsomes assessed as (S)-mephenytoin 4'-hydroxylation preincubated for 15 mins by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2D6 in human liver microsomes assessed as bufuralol 1'-hydroxylation preincubated for 15 mins by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2E1 in human liver microsomes assessed as chlorzoxazone 6-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of...More data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2C19 in human liver microsomes assessed as (S)-mephenytoin 4'-hydroxylation after 3 mins by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation preincubated for 15 mins by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence...More data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2D6 in human liver microsomes assessed as bufuralol 1'-hydroxylation after 3 mins by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2C9 in human liver microsomes assessed as paclitaxel 6alpha-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPHMore data for this Ligand-Target Pair
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence...More data for this Ligand-Target Pair
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation preincubated for 15 mins by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of CYP2E1 in human liver microsomes assessed as chlorzoxazone 6-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of...More data for this Ligand-Target Pair
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of CYP2D6 in human liver microsomes assessed as bufuralol 1'-hydroxylation preincubated for 15 mins by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of CYP2C19 in human liver microsomes assessed as (S)-mephenytoin 4'-hydroxylation preincubated for 15 mins by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of CYP2C9 in human liver microsomes assessed as paclitaxel 6alpha-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence ...More data for this Ligand-Target Pair
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of CYP2C8 in human liver microsomes assessed as paclitaxel 6alpha-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence ...More data for this Ligand-Target Pair
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of CYP2B6 in human liver microsomes assessed as bupropion hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPHMore data for this Ligand-Target Pair
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of CYP1A2 in human liver microsomes assessed as phenacetin O-deethylation preincubated for 15 mins by LC-MS/MS analysis in presence of NAD...More data for this Ligand-Target Pair
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPHMore data for this Ligand-Target Pair
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 3 mins by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of CYP2E1 in human liver microsomes assessed as chlorzoxazone 6-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPHMore data for this Ligand-Target Pair
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of CYP2D6 in human liver microsomes assessed as bufuralol 1'-hydroxylation after 3 mins by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of CYP2C19 in human liver microsomes assessed as (S)-mephenytoin 4'-hydroxylation after 3 mins by LC-MS/MS analysisMore data for this Ligand-Target Pair